[
  {
    "question": "Patient with relapsing remitting MS with no disease activity for two years what is the percentage of Benign MS",
    "option_a": "5%",
    "option_b": "10%",
    "option_c": "15",
    "option_d": "20",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Benign MS refers to a course of multiple sclerosis in which patients experience minimal disability over many years despite evidence of disseminated demyelination. It is usually defined retrospectively (often after 15 years) using an Expanded Disability Status Scale (EDSS) threshold (for example, <3). Although demyelinating lesions are present, patients with benign MS tend to have limited inflammatory activity, lower cumulative axonal loss, and fewer new lesions over time. This results in a relatively stable neurological status compared to other MS subtypes. Patients with benign MS generally retain good neurological function with minimal disability, often maintaining employment and daily activities. It is important to note that early stability (such as two years of no overt activity) does not guarantee a benign long\u2010term course. Determining benign MS involves retrospective assessment over a prolonged period (commonly 15 years). Differential diagnoses include relapsing\u2010remitting and secondary progressive MS. Serial clinical evaluations and MRI studies are used to monitor disease activity and progression. Although classified as \u2018benign,\u2019 patients are still managed with standard disease\u2010modifying therapies (DMTs) to prevent relapses and MRI activity. In pregnant or lactating patients, the risk\u2013benefit profile of continuing DMTs is carefully weighed, and some therapies may be delayed or switched according to current international guidelines. Option A (5%) is too low, Option B (10%) is within the range but not as commonly cited, and Option D (20%) is slightly above the typical estimate. Literature frequently approximates benign MS at around 15%, making Option C (15%) the best answer. 1. Benign MS is only determined in retrospect, often after 15 years of minimal disability. 2. Short periods of stability do not necessarily predict a benign long\u2010term course. 3. Continuous monitoring is essential even in seemingly benign disease. Recent studies indicate that between 10% and 20% of MS patients may eventually exhibit a benign course, with many sources commonly citing around 15%. Advances in imaging and biomarkers are being researched to better predict long\u2010term prognosis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following is a feature of optic neuritis due to MS?",
    "option_a": "Papillitis with papilledema",
    "option_b": "Bilateral ON",
    "option_c": "Pain with eye movement",
    "option_d": "Star shape in the retina",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis is an inflammatory demyelinating condition of the optic nerve that is frequently associated with multiple sclerosis. It typically presents with unilateral visual impairment and ocular pain. The demyelination of the optic nerve fibers leads to impaired nerve conduction and inflammation. The inflammation triggers pain, especially during eye movements, due to stretching of the affected nerve. Patients with MS-associated optic neuritis often experience acute, unilateral vision loss accompanied by pain on eye movement. A relative afferent pupillary defect (RAPD) is commonly observed on examination. Differential diagnoses include ischemic optic neuropathy, neuromyelitis optica spectrum disorder (often bilateral), and other inflammatory or compressive optic neuropathies. MRI of the brain and orbits, along with a thorough ocular examination, helps in differentiating these conditions. Acute treatment is generally high-dose intravenous corticosteroids (such as methylprednisolone), which help reduce inflammation and speed up recovery. For pregnant or lactating patients, steroid therapy is used judiciously after considering potential risks and benefits. Option A (Papillitis with papilledema) is incorrect because true papilledema is due to raised intracranial pressure, not typical in MS optic neuritis. Option B (Bilateral ON) is not common in MS, where the involvement is usually unilateral. Option D (Star shape in the retina) is not a recognized feature. Option C (Pain with eye movement) is the classic presenting feature and is therefore correct. 1. Pain with eye movement is a hallmark symptom of MS-related optic neuritis. 2. The condition is most often unilateral. 3. Early intervention with steroids may speed up recovery despite similar long-term outcomes. Recent clinical trials have confirmed that while high-dose steroids expedite visual recovery in optic neuritis, they have little impact on the final visual outcome. Advanced imaging continues to refine the diagnostic process in optic neuritis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with features of PML (confusion) known case of MS on Natalizumab with MRI showing WM lesion in the left occipital area what to do",
    "option_a": "Stop Natalizumab",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection caused by reactivation of the JC virus, commonly seen in patients under immunosuppressive therapies such as natalizumab. Natalizumab inhibits leukocyte adhesion and migration into the central nervous system, resulting in decreased immunosurveillance and predisposition to JC virus reactivation, which leads to demyelination in the brain. Patients with PML typically present with cognitive changes, confusion, and focal neurological deficits. In this case, confusion along with a white matter lesion in the occipital area on MRI are red flags suggestive of PML. Differentiating PML from an MS flare is critical. While MS relapses tend to be inflammatory with enhancing lesions, PML lesions are typically non-enhancing, asymmetric, and seen in the subcortical white matter. CSF analysis for JC virus DNA via PCR is an important diagnostic tool. The immediate step in managing suspected PML is to stop natalizumab to halt further immunosuppression. Subsequent treatments may include plasma exchange (PLEX) to accelerate the clearance of natalizumab. In pregnancy, cessation is crucial, although any alterations in therapy should be based on careful risk\u2013benefit assessment. Lactation considerations similarly require multidisciplinary evaluation. Option A (Stop Natalizumab) is correct as the immediate measure to limit the progression of PML. Other potential options (if provided) such as continuing therapy or alternative immunomodulatory strategies would be contraindicated. 1. Any suspicion of PML in a natalizumab-treated patient necessitates immediate drug discontinuation. 2. MRI and CSF analysis are key to confirming the diagnosis. 3. Plasma exchange is often used following discontinuation to expedite the removal of natalizumab. Recent guidelines and studies emphasize the importance of early identification and immediate natalizumab cessation in suspected PML cases, with plasma exchange being increasingly adopted to aid in drug clearance and promote immune reconstitution.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known to have MS on Natalizumab came with MS relapse (left leg weakness with incontinence) no features in Q of PML what to do",
    "option_a": "IVIG",
    "option_b": "Prednisone",
    "option_c": "Plasma exchange",
    "option_d": "Methylprednisolone.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "An acute relapse of multiple sclerosis manifests as the development or worsening of neurological deficits due to new inflammatory demyelination. High-dose intravenous corticosteroids are the standard treatment to reduce inflammation and hasten recovery. During an MS relapse, an immune-mediated inflammatory process results in demyelination and disruption of nerve conduction. Methylprednisolone reduces inflammation by suppressing immune activity, thereby facilitating recovery of neurological function. In this patient, the presentation with left leg weakness and incontinence is consistent with an MS relapse rather than PML, especially in the absence of cognitive decline or PML-specific MRI findings. The differential involves distinguishing an MS relapse from PML and other causes of neurological deterioration such as spinal cord compression or infection. MRI findings and clinical history are key to this differentiation. First-line management of an MS relapse is high-dose intravenous methylprednisolone (typically 1 gram daily for 3\u20135 days). For steroid-refractory cases, plasma exchange may be considered. In pregnancy, high-dose steroids can be used after thorough risk assessment (noting possible risks during the first trimester), and short courses are generally considered acceptable in lactation with monitoring. Option D (Methylprednisolone) is the correct treatment option for acute relapse management. Option A (IVIG) is not standard for MS relapses, Option B (oral prednisone) is less effective than IV formulations for acute relapses, and Option C (Plasma exchange) is reserved for cases that do not respond to steroids. 1. High-dose IV methylprednisolone is the cornerstone of acute MS relapse therapy. 2. Distinguishing MS relapse from PML is critical for appropriate management. 3. Treatment plans may need to be adjusted for pregnancy and lactation after careful consideration. Updated clinical guidelines continue to support the use of high-dose IV methylprednisolone as first-line therapy for MS relapses, with evidence showing accelerated recovery and reduction in inflammatory markers. For steroid-resistant relapses, plasma exchange is increasingly recommended based on recent studies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following considered as red flag in multiple sclerosis?",
    "option_a": "Extensive spinal lesion",
    "option_b": "Bilateral INO",
    "option_c": "Enhancing lesion more than 3 months",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "In the diagnosis of multiple sclerosis (MS), red flags are clinical or radiologic features that are atypical for MS and should prompt reconsideration of the diagnosis. MS lesions typically demonstrate a defined course of activity with transient gadolinium enhancement. Active MS plaques enhance on MRI due to blood\u2013brain barrier disruption, but this enhancement usually lasts only for 3\u20136 weeks. An enhancing lesion persisting for more than 3 months is inconsistent with typical MS lesion dynamics and raises the concern for an alternative pathology such as neoplasm or an inflammatory lesion of a different etiology. A prolonged enhancing lesion (>3 months) would not correlate with the expected transient inflammatory activity seen in MS. Clinically, MS relapses are acute and the imaging findings are expected to evolve; persistent enhancement suggests an abnormal process that requires further investigation. For suspected MS, MRI remains the key diagnostic tool. Differential diagnoses to consider when faced with atypical MRI findings include neuromyelitis optica spectrum disorder (especially if there are extensive spinal lesions), central nervous system lymphoma, neurosarcoidosis, and other inflammatory or neoplastic processes. Serial imaging and additional tests (CSF analysis, evoked potentials) can help differentiate these conditions. When red flag features are identified, re\u2010evaluation of the diagnosis is mandatory. This may include additional imaging, possibly a biopsy if a neoplasm is suspected, and consultation with specialists. Although this question is diagnostic, if treatment were indicated, current MS guidelines support early initiation of disease-modifying therapies (DMTs) after a firm diagnosis. In women who are pregnant or lactating, treatment options may need to be adjusted to ensure fetal and neonatal safety. Option A (Extensive spinal lesion) is a red flag because longitudinally extensive spinal cord lesions (involving three or more vertebral segments) are more typically seen in neuromyelitis optica spectrum disorders rather than MS. Option B (Bilateral INO) is actually seen in MS. Option C (Enhancing lesion more than 3 months) is correct because MS lesions are expected to enhance only transiently. Option D is blank. 1. MS plaques usually enhance for only a few weeks; persistent enhancement should raise concern. 2. Extensive spinal lesions are atypical for MS and may suggest alternative diagnoses like NMO. Recent MRI studies and the latest revisions of the McDonald criteria emphasize that imaging features inconsistent with typical time-course dynamics (like persistent enhancement) should prompt reconsideration of the MS diagnosis. This is supported by ongoing research into atypical demyelinating presentations.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Young female Patient with right leg weakness and incontinence with now previous neurological complaint with MRI image attached (flair showing two periventricular lesions, and T1 with C+ showing one lesion enhancing, and whole spine MRI T2 showing multiple small lesions) asking what is the diagnosis",
    "option_a": "Multiple Sclerosis",
    "option_b": "CIS",
    "option_c": "RIS",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The McDonald criteria for MS require evidence of dissemination in space (lesions in different characteristic locations) and time (lesions occurring at different points, shown by a mix of enhancing and non-enhancing lesions). MS is an immune-mediated demyelinating disease of the central nervous system. The appearance of both enhancing (active) and non-enhancing (older) lesions on MRI indicates that demyelinating events have occurred at different times. A young female with right leg weakness and incontinence, along with MRI findings that include periventricular lesions (common in MS) and multiple spinal lesions, fits the clinical picture of MS rather than a Clinically Isolated Syndrome (CIS) or Radiologically Isolated Syndrome (RIS). The clinical symptoms parallel the multifocal CNS involvement typical of MS. Diagnosis is confirmed by careful evaluation of clinical history and MRI findings. Differential diagnoses include CIS (if there were only one clinical episode), RIS (if the patient were asymptomatic despite MRI abnormalities), neuromyelitis optica spectrum disorder (which typically shows longitudinal extensive transverse myelitis), and acute disseminated encephalomyelitis (transient post-infectious demyelination). The presence of an enhancing lesion along with non-enhancing lesions aids in demonstrating dissemination in time. Current guidelines recommend initiating disease-modifying therapy (DMT) at the time of diagnosis in patients with definite MS. First-line DMTs include interferon-beta agents, glatiramer acetate, and newer oral agents. In pregnancy, treatment decisions require careful risk\u2013benefit analysis; many first-line DMTs are avoided during pregnancy and breastfeeding, so treatment may be postponed or switched to pregnancy-compatible agents. Option A (Multiple Sclerosis) is correct because the combination of clinical symptoms and MRI findings (both brain and spinal lesions with evidence of dissemination in time and space) confirms the diagnosis. Option B (CIS) would be considered if there had been only one clinical episode without clear evidence of dissemination in time. Option C (RIS) is not applicable here since the patient is symptomatic. 1. Look for lesions in characteristic locations (periventricular, juxtacortical, infratentorial, and spinal cord) to fulfill dissemination in space. 2. The presence of both enhancing and non-enhancing lesions is indicative of dissemination in time. Recent updates to the McDonald criteria have streamlined the diagnosis of MS by incorporating MRI findings more effectively. Ongoing research continues to refine the role of early DMT initiation to improve long-term outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_22.png"
  },
  {
    "question": "Which of the following DMT medication cause paresthesia?",
    "option_a": "Teriflunomide",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Disease-modifying therapies (DMTs) for MS vary in their mechanisms and side effect profiles. Knowledge of these adverse effects is crucial for monitoring and patient counseling. Teriflunomide is an oral immunomodulatory agent that inhibits pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes. It has been associated with several side effects, including gastrointestinal disturbances, liver enzyme elevations, hair thinning, and in some cases, neurological symptoms such as paresthesia, likely related to peripheral neuropathy. Patients on teriflunomide may experience paresthesias, which present as tingling or numbness in the extremities. Recognizing these symptoms early allows clinicians to evaluate the severity and consider dose adjustments or a switch in therapy if necessary. When patients report paresthesia while on DMT, clinicians should conduct a comprehensive review of medication history, perform a neurological exam, and consider other causes of peripheral neuropathy. Differential diagnoses include diabetic neuropathy, vitamin deficiencies, or other medication-induced neuropathies. Clinicians must monitor liver function tests and inquire about neuropathic symptoms. If significant paresthesia develops, dose modification or a switch to an alternative DMT may be warranted. Importantly, due to its teratogenic potential, teriflunomide is contraindicated in pregnancy; women of childbearing potential must use effective contraception, and if pregnancy occurs, an accelerated elimination protocol is recommended. Option A (Teriflunomide) is correct because it is known to potentially cause paresthesia through its propensity to induce peripheral neuropathy. Other options (though not provided here) would be assessed based on their known side effect profiles, but among the common DMTs, teriflunomide is most notably associated with this complaint. 1. Always counsel patients on teriflunomide regarding the risk of peripheral neuropathy and other common side effects. 2. Teriflunomide is contraindicated in pregnancy due to its known teratogenicity, necessitating careful pre-treatment planning. Post-marketing surveillance and recent studies have continued to document the adverse event profile of teriflunomide, reinforcing the need for routine monitoring. Newer research is focused on comparing the side effect profiles of DMTs to guide personalized therapy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "MS patient, no relapse in MRI for the last 2 years complaining of fatigue",
    "option_a": "??",
    "option_b": "modafinil",
    "option_c": "amantadine",
    "option_d": "escitalopram",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Fatigue is one of the most common and debilitating symptoms of MS. Pharmacologic management aims to alleviate fatigue in patients whose disease is otherwise stable. The etiology of MS-related fatigue is multifactorial involving immunologic dysregulation, neurotransmitter imbalances, and deconditioning. Amantadine is thought to work through dopaminergic modulation and NMDA receptor antagonism, thereby improving energy levels and reducing fatigue. In patients with MS who have been stable (no relapses and no new MRI activity) but experience significant fatigue, symptomatic treatment is indicated. Although fatigue can be related to depression or sleep disturbances, in the absence of these, targeting fatigue directly with agents like amantadine can be beneficial. A thorough evaluation is essential to exclude other causes of fatigue such as anemia, thyroid dysfunction, sleep disorders, or depression. After a detailed clinical and laboratory workup, pharmacotherapy may be initiated if fatigue is attributed to MS. According to current guidelines, amantadine is often used as a first-line agent for managing MS fatigue despite modest efficacy. Alternatives include modafinil, which is sometimes employed when amantadine is ineffective or contraindicated. In women who are pregnant or lactating, the use of these medications requires a careful benefit\u2013risk assessment as both amantadine and modafinil are generally classified as Category C, meaning that therapy should be considered only if the potential benefits justify any potential risks to the fetus or infant. Option B (modafinil) is an alternative treatment for fatigue but is not the traditionally endorsed first-line agent for MS fatigue. Option C (amantadine) is the most commonly used agent in this scenario, as supported by clinical practice and guidelines. Option D (escitalopram) is an SSRI that may address fatigue secondary to depression but is not directly indicated for primary MS fatigue when depression is not the primary issue. 1. Amantadine remains the first-line pharmacologic agent for MS-related fatigue, even though its efficacy may be modest. 2. Always rule out confounding factors like sleep disorders and depression before initiating treatment for MS fatigue. Recent studies and meta-analyses have shown variable efficacy for pharmacologic treatment of MS fatigue; however, amantadine continues to be used widely due to its favorable risk\u2013benefit profile in the absence of active disease. Ongoing research is evaluating newer agents and non-pharmacologic interventions for better fatigue control.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_22.png"
  },
  {
    "question": "16-year-old patient presented with confusion; MRI attached showing bilateral white matter changing.",
    "option_a": "ADEM",
    "option_b": "Primary CNS angiitis",
    "option_c": "Multiple sclerosis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disorder of the central nervous system that principally affects children and adolescents. It typically occurs after an infectious illness or immunization, representing a monophasic process. ADEM is believed to be an autoimmune reaction triggered by an antigenic stimulus (such as a virus or vaccine) leading to widespread inflammation and demyelination in the brain\u2019s white matter. Perivenular inflammation with demyelination characterizes the pathology, and more recent studies indicate involvement of both cellular and humoral immune mechanisms. Patients often present with an acute onset of multifocal neurological deficits, including confusion, headache, fever, and sometimes seizures. The clinical scenario of a 16\u2010year\u2010old with confusion and bilateral white matter changes on MRI is typical for ADEM, contrasting with disorders like multiple sclerosis which often have a relapsing-remitting course. MRI is the cornerstone for diagnosing ADEM, typically demonstrating large, bilateral, and often asymmetric or confluent lesions in the white matter. Differential diagnoses include multiple sclerosis (characterized by periventricular plaques and a relapsing course) and primary CNS vasculitis (usually in older patients with more focal deficits). Lumbar puncture and exclusion of infectious causes are also part of the workup. First-line treatment for ADEM is high-dose intravenous corticosteroids (e.g., IV methylprednisolone for 3\u20135 days) followed by an oral steroid taper. In refractory cases, plasma exchange or IV immunoglobulins may be considered. In pregnancy and lactation, corticosteroids are generally safe, but treatment plans should involve multidisciplinary risk\u2013benefit discussions. Option A (ADEM) is correct because the clinical features (age, confusion, and bilateral white matter lesions) are typical of ADEM. Option B (Primary CNS angiitis) is less likely given the patient\u2019s age and presentation. Option C (Multiple sclerosis) is usually characterized by a relapsing-remitting course and distinct lesion distribution, making it a less likely diagnosis in this acute setting. 1. ADEM is most common in children and adolescents, typically following a viral infection or immunization. 2. MRI findings in ADEM show bilateral, large, and often confluent white matter lesions. 3. High-dose steroids are the mainstay of treatment and usually lead to rapid improvement. Recent studies and guidelines continue to support the use of high-dose corticosteroids as first-line therapy for ADEM. There is growing evidence for the role of plasma exchange in patients who do not respond to steroids, and research into specific biomarkers is ongoing to aid in differentiation from other demyelinating disorders.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with sensory neuronopathy you suspected malignancy what antibodies you will look for:",
    "option_a": "anti Hu",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Sensory neuronopathy is a paraneoplastic neurological syndrome where an autoimmune reaction, usually triggered by a malignancy, injures the dorsal root ganglia resulting in profound sensory deficits. The pathophysiology involves an immune-mediated attack, often triggered by onconeural antigens expressed by tumors. Anti-Hu antibodies (ANNA-1) target neuronal nuclear antigens, leading to neuronal damage in the peripheral nervous system, particularly affecting the sensory neurons. Patients typically present with subacute onset of sensory deficits, including numbness, paresthesias, pain and, sometimes, ataxia. The presence of anti-Hu antibodies strongly suggests an underlying malignancy such as small-cell lung carcinoma, which is why their detection is critical in patients with sensory neuronopathy. Diagnosis involves serologic testing for paraneoplastic antibodies (e.g., anti-Hu) in addition to a thorough search for an occult malignancy using imaging like CT of the chest, abdomen, and pelvis, and possibly PET scanning. Differential diagnoses include other causes of sensory neuropathy (e.g., vitamin deficiencies, diabetes, toxic exposures), which can be distinguished based on clinical history and laboratory results. Management involves treating the underlying malignancy which is paramount. Immunomodulatory therapies such as high-dose corticosteroids, IVIG, or plasmapheresis may be used, but their effectiveness is often limited. In pregnant or lactating patients, caution is needed; steroids are relatively safe but other immunomodulatory therapies may require adjustment or avoidance depending on gestational age and lactation status. Option A (anti-Hu) is correct because anti-Hu antibodies are the classic marker in patients with paraneoplastic sensory neuronopathy. The absence of other options in this question further emphasizes the role of anti-Hu in this setting. 1. Anti-Hu antibodies are most often associated with small-cell lung carcinoma in paraneoplastic sensory neuronopathy. 2. Early detection of these antibodies prompts an aggressive search for occult malignancy. 3. Sensory neuronopathy can present with profound and disabling sensory dysfunction that is often irreversible if not treated early. Current literature supports anti-Hu antibody testing as a critical component of the paraneoplastic panel in cases of sensory neuronopathy. Recent guidelines emphasize comprehensive malignancy screening once these antibodies are identified and note that while immunotherapy has limited success, early oncologic treatment is crucial.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of hearing loss and new impaired vision with MRI showing high intensity flare sequence in the corpus callosum what\u2019s the diagnosis",
    "option_a": "Susac Syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Susac Syndrome is a rare autoimmune microangiopathy involving the small vessels of the brain, retina, and inner ear. It is characterized by a classic clinical triad: encephalopathy, branch retinal artery occlusions (leading to visual impairment), and sensorineural hearing loss. The underlying mechanism involves an immune-mediated endotheliopathy that causes microinfarctions in the affected tissues. MRI findings, particularly high-intensity lesions on FLAIR sequences in the corpus callosum (often referred to as 'snowball' lesions), are highly characteristic of the syndrome. Patients may present with a combination of visual disturbances (due to retinal artery occlusions), hearing loss, and neurological deficits such as confusion or cognitive impairment. The involvement of the corpus callosum on imaging strongly supports the diagnosis of Susac Syndrome. The diagnosis is made through a combination of clinical findings and supportive investigations. MRI findings (corpus callosum lesions), fluorescein angiography to detect retinal arterial occlusions, and audiometry for sensorineural hearing loss are all central to diagnosis. Differential diagnoses include multiple sclerosis and ADEM; however, the triad present in Susac Syndrome helps distinguish it. The management typically involves immunosuppression with high-dose corticosteroids as first-line treatment. Intravenous immunoglobulin and other immunosuppressive agents such as cyclophosphamide or mycophenolate mofetil may be used as adjuncts, especially in more severe or refractory cases. In pregnancy, corticosteroids are generally acceptable, but agents like cyclophosphamide are contraindicated due to teratogenic risk; alternative immunosuppressants with better safety profiles need to be considered. Option A (Susac Syndrome) is correct because the combination of hearing loss, visual impairment, and corpus callosum lesions on MRI fits the classic triad of Susac Syndrome. Other options, if presented, would not adequately account for the unique constellation of symptoms seen in this disorder. 1. Susac Syndrome is characterized by a triad: encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. 2. High-intensity lesions on FLAIR MRI sequences in the corpus callosum are highly suggestive of this syndrome. 3. Early immunosuppressive treatment can improve long-term outcomes. Recent research highlights the importance of early diagnosis and aggressive immunosuppressive therapy in Susac Syndrome to prevent irreversible damage. Ongoing studies are investigating the optimal duration and combination of therapies, and updated guidelines are emerging to tailor treatment, particularly in special populations such as pregnant patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Dx of 1ry CNS angiitis",
    "option_a": "CTA",
    "option_b": "Biopsy",
    "option_c": "MRI",
    "option_d": "Color duplex sonography",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Primary CNS angiitis, also known as primary angiitis of the CNS (PACNS), is a rare form of vasculitis limited to the brain and spinal cord. It involves inflammation of cerebral blood vessels leading to various neurological deficits. The process is characterized by immune-mediated inflammation of the vessel walls, resulting in vessel narrowing, occlusion, and subsequent ischemic injury in the brain. The inflammatory changes can be patchy, affecting vessels of various sizes. Patients with PACNS can present with a wide range of symptoms including headaches, cognitive impairment, focal neurological deficits, and seizures. Because of its variable presentation and non-specific imaging findings, PACNS is often a diagnosis of exclusion. Although advanced imaging modalities such as MRI and cerebral angiography (CTA or conventional angiography) can suggest vasculitic changes, a definitive diagnosis requires a brain biopsy, which remains the gold standard. Differential diagnoses to consider include reversible cerebral vasoconstriction syndrome (RCVS), secondary CNS vasculitis (due to systemic inflammatory conditions), and infections. The mainstay of treatment for PACNS is high-dose corticosteroids, often in combination with immunosuppressive agents such as cyclophosphamide for induction of remission. In the context of pregnancy, corticosteroids are relatively safe when monitored closely; however, cyclophosphamide is contraindicated due to its teratogenic potential and alternative immunosuppressants with safer profiles must be considered. Option B (Biopsy) is correct as brain biopsy is considered the gold standard for diagnosing primary CNS angiitis. Option A (CTA) and Option C (MRI) may suggest vasculitic changes but lack the specificity required for a definitive diagnosis. Option D (Color duplex sonography) is used for evaluating extracranial vasculature and is not applicable to the small intracranial vessels affected in PACNS. 1. Brain biopsy remains the definitive diagnostic modality in suspected PACNS despite advances in imaging techniques. 2. PACNS can present with a wide range of neurological symptoms making early diagnosis challenging. 3. Immunosuppressive therapy is the cornerstone of treatment with careful consideration in special populations like pregnant patients. Current guidelines continue to endorse brain biopsy as the gold standard for diagnosing PACNS. Recent literature emphasizes the importance of early diagnosis and treatment to prevent irreversible neurological damage, and new immunomodulatory regimens are being studied to improve outcomes while considering safety in vulnerable populations such as pregnant and lactating women.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Known to have Breast cancer, came with opsoclonus myoclonus:",
    "option_a": "(Anti",
    "option_b": "(Anti",
    "option_c": "(Anti",
    "option_d": "(Anti",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic neurological syndrome that occurs when an immune response against tumor antigens cross-reacts with neuronal tissue. In the setting of breast cancer, the appearance of OMS should raise suspicion for an antibody-mediated process, with Anti-Ri (ANNA-2) being the prototypical antibody linked to this syndrome. Anti-Ri antibodies target intracellular neuronal antigens, specifically the NOVA family of proteins, which are essential for proper RNA splicing in neurons. Their binding leads to dysfunction particularly in the brainstem and cerebellum, areas involved in coordinated motor control, resulting in opsoclonus (rapid, multidirectional eye movements) and myoclonus (sudden, brief muscle jerks). This immune-mediated attack manifests as a paraneoplastic phenomenon associated with breast (and sometimes small cell lung) cancers. Patients with breast cancer who develop OMS typically present with chaotic eye movements (opsoclonus) and involuntary muscle jerks (myoclonus). This presentation is distinctly different from classical paraneoplastic cerebellar degeneration, which is more commonly linked to Anti-Yo antibodies and manifests as progressive cerebellar ataxia without opsoclonus. The identification of Anti-Ri in the serum reinforces the diagnosis of a paraneoplastic syndrome linked to the underlying malignancy. The evaluation involves a detailed neurological examination, serum and CSF testing for paraneoplastic antibodies, and neuroimaging (MRI of the brain) to rule out metastases or other structural causes. Differential diagnoses include paraneoplastic cerebellar degeneration (commonly associated with Anti-Yo antibodies), stiff-person syndrome (associated with Anti-amphiphysin), or brainstem encephalitis (sometimes linked with Anti-Ma2 antibodies). The specific detection of Anti-Ri antibodies, in the proper clinical context, is highly suggestive of paraneoplastic OMS. The mainstay of management is treating the underlying malignancy combined with immunotherapy. First-line immunomodulatory therapies include high-dose corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis to reduce antibody titers. In patients of childbearing age or those who are pregnant, therapies must be chosen carefully: corticosteroids can be used with caution and IVIG is generally considered safe. Additionally, oncologic treatment (surgery, chemotherapy, radiation) should be optimized. Long-term neurologic rehabilitation is also critical. Option a (Anti-Yo) is incorrect because these antibodies are typically linked to cerebellar degeneration without opsoclonus. Option b (Anti-Ri) is correct as it is most commonly associated with OMS in the setting of breast cancer. Option c (Anti-amphiphysin) is linked more with stiff-person syndrome and paraneoplastic encephalomyelitis. Option d (Anti-Ma2) is associated with limbic and brainstem encephalitis in young men with testicular tumors, not with OMS. 1. In breast cancer patients presenting with opsoclonus and myoclonus, always consider a paraneoplastic etiology with Anti-Ri antibodies. 2. Early recognition and treatment of paraneoplastic syndromes may mitigate neurologic damage. 3. Differentiating OMS from cerebellar degeneration is crucial because the underlying antibody profile and treatment strategies differ. Recent studies emphasize the importance of early antibody detection in PNS as a biomarker for tailored immunotherapy and oncologic management. Updated guidelines support aggressive treatment of the underlying cancer along with immunomodulatory therapy to improve neurologic outcomes in patients with paraneoplastic OMS.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Anaphylaxis with Natalizumab\na) Continue  b) D/C  c) Decrease the rate",
    "option_a": "Continue",
    "option_b": "D/C",
    "option_c": "Decrease the rate",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab, a monoclonal antibody used in multiple sclerosis (MS) and Crohn\u2019s disease, can cause infusion-related adverse events including hypersensitivity reactions and even anaphylaxis. Understanding the management of severe allergic reactions such as anaphylaxis is critical in the context of monoclonal antibody infusions. Anaphylaxis is a severe, potentially life-threatening type I hypersensitivity reaction mediated by IgE antibodies. Upon infusion of natalizumab in a sensitized individual, a rapid immunologic cascade can occur, leading to mast cell degranulation, histamine release, and the systemic manifestations of anaphylaxis (e.g., hypotension, bronchospasm, and urticaria). Clinically, patients experiencing anaphylaxis present with rapid onset of symptoms including respiratory distress, cardiovascular collapse, and cutaneous signs like hives or angioedema. In the context of natalizumab infusion, recognizing these signs promptly is essential to prevent further deterioration. Diagnosis is primarily clinical, based on the sudden onset of symptoms following exposure to the drug. Differential diagnoses include mild infusion reactions or cytokine-release syndromes. The rapid progression of symptoms in anaphylaxis, however, distinguishes it from less severe infusion-related reactions. First-line management of anaphylaxis involves immediate discontinuation of the offending agent (natalizumab) and prompt administration of intramuscular epinephrine. Additional supportive measures include oxygen supplementation, intravenous fluids, and antihistamines. For pregnant or lactating patients, epinephrine remains the treatment of choice because the maternal benefits outweigh the potential fetal risks in life-threatening situations. Subsequent management may include corticosteroids and observation in a monitored setting. Option a (Continue) is incorrect because continuing the infusion can exacerbate the reaction. Option b (D/C) is correct as immediate discontinuation is essential in managing anaphylaxis. Option c (Decrease the rate) is inadequate in cases of anaphylaxis, where the reaction is severe and demands complete cessation of the drug. 1. Immediate recognition and discontinuation of natalizumab are critical when anaphylaxis occurs. 2. In any suspected anaphylactic reaction to monoclonal antibodies, epinephrine is the first-line medication. 3. Even in pregnant patients, the immediate management of anaphylaxis remains the same due to the life-threatening nature of the condition. Recent guidelines and infusion center protocols emphasize that any sign of anaphylaxis with monoclonal antibody infusions warrants immediate drug cessation. Studies have reinforced the safety and efficacy of standard anaphylaxis management protocols, including the use of epinephrine, even in pregnant and lactating patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "PML case asking about treatment:\na) IVIG  b) Steroid  c) Plex",
    "option_a": "IVIG",
    "option_b": "Steroid",
    "option_c": "Plex",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the JC virus. It is primarily seen in immunocompromised individuals, including those receiving immunomodulatory therapies like natalizumab for multiple sclerosis. PML results from the reactivation of JC virus in the setting of impaired immune surveillance, leading to lytic infection of oligodendrocytes and subsequent demyelination. In patients on natalizumab, the drug hinders lymphocyte migration into the CNS, promoting viral reactivation. Plasmapheresis (plasma exchange) is used to rapidly remove natalizumab from circulation to restore immune function and allow the immune system to target the JC virus. Clinically, PML can present with a variety of neurological deficits that depend on the brain regions affected. These include motor weakness, cognitive deficits, visual changes, and ataxia. In the context of natalizumab therapy, early recognition through clinical suspicion and neuroimaging is pivotal since prompt drug clearance via plasma exchange can be life-saving. Diagnosis of PML involves MRI findings of multifocal white matter lesions (often without mass effect or contrast enhancement initially), JC virus detection by PCR in the cerebrospinal fluid, and clinical correlation. Differential diagnoses include MS exacerbation (which usually has different imaging characteristics) and other demyelinating processes. The cornerstone of managing natalizumab-associated PML is immune reconstitution by stopping the drug and using plasma exchange to accelerate its clearance. First-line interventions include immediate cessation of the offending agent and institutional plasmapheresis. Adjunctive therapies, such as corticosteroids, may be considered in managing PML-associated immune reconstitution inflammatory syndrome (IRIS). In pregnant or lactating patients, treatment decisions must balance the risk of progressive neurological decline with the safety of the foetus or infant; though plasmapheresis is generally considered safe, multidisciplinary consultation is advised. Option a (IVIG) is not supported by evidence as a primary treatment for PML. Option b (Steroid) may be reserved for IRIS after immune reconstitution but is not the main treatment for PML itself. Option c (Plex) is the correct answer because plasmapheresis facilitates the removal of natalizumab, thereby restoring immune surveillance against the JC virus. 1. Early identification of PML in patients on natalizumab is critical. 2. Plasmapheresis is the primary intervention to expedite drug clearance and immune system recovery. 3. Watch for signs of IRIS following immune reconstitution, which may require additional management. Emerging research continues to validate the role of plasmapheresis in natalizumab-associated PML to rapidly reverse immunosuppression. Recent guideline updates underscore the importance of prompt drug discontinuation and immune reconstitution in improving outcomes in PML cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "MS prognosis\n a) MRI of brain\n b) OCB",
    "option_a": "(MRI of brain) is correct as it provides quantitative data on lesion burden and activity, directly correlating with prognosis in MS. Option b (OCB) is less useful for prognostication because, although it supports the diagnosis of MS by indicating intrathecal immunoglobulin synthesis, it does not predict disease course or severity.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuroimmunology",
    "explanation": "In multiple sclerosis (MS), prognostication involves assessing the disease burden and activity over time. MRI has become a critical tool in evaluating the number, size, and activity of demyelinating lesions, making it highly valuable for prognosis compared to other diagnostic markers. MS is characterized by immune-mediated demyelination and axonal injury. MRI can detect both active (gadolinium-enhancing) lesions and chronic lesions, as well as brain atrophy, which are markers of disease progression and correlate with clinical disability. In contrast, oligoclonal bands (OCBs) in the cerebrospinal fluid indicate intrathecal IgG synthesis and assist in diagnosis rather than predicting disease outcome. The number and activity of lesions seen on MRI have been shown to correlate with relapse rates and future disability. Gadolinium-enhancing lesions suggest active inflammation, which is predictive of near-term relapses. Meanwhile, the presence of OCBs, although supportive in the diagnosis of MS, is common and does not differentiate between benign and aggressive disease courses. For prognostication in MS, serial MRI studies are recommended to monitor lesion load and brain atrophy. Differential prognostic markers include clinical relapse history, disability scales (like the EDSS), and neuroimaging findings. OCBs, while useful diagnostically, lack specificity for prognostic evaluation. Management of MS involves disease-modifying therapies (DMTs) tailored to the individual's MRI findings and relapse history. First-line treatments include interferon-beta, glatiramer acetate, or newer oral agents; escalation may be warranted based on disease activity. For pregnant or lactating patients, treatment choices must protect both maternal and fetal health, with certain DMTs being contraindicated or used with caution. Regular MRI monitoring is essential for adjusting therapy and assessing prognosis. Option a (MRI of brain) is correct as it provides quantitative data on lesion burden and activity, directly correlating with prognosis in MS. Option b (OCB) is less useful for prognostication because, although it supports the diagnosis of MS by indicating intrathecal immunoglobulin synthesis, it does not predict disease course or severity. 1. MRI is the most valuable tool in assessing MS prognosis due to its ability to quantify lesion load and detect active inflammation. 2. Gadolinium enhancement on MRI is a reliable indicator of current disease activity. 3. OCBs support MS diagnosis but do not inform on the future disability progression. Recent studies have further reinforced the predictive value of MRI metrics in MS, showing that measures such as T2 lesion load, gadolinium enhancement, and brain atrophy rates are closely linked to long-term outcomes. Updated guidelines recommend MRI as the cornerstone of both diagnosis and disease monitoring in MS.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Contraindicated if the patient has history of seizure",
    "option_a": "(Alemtuzumab) is an immunomodulatory agent with no direct effect on neuronal excitability; Option B (Dalfampridine) increases neuronal excitability and lowers the seizure threshold, making it contraindicated in patients with a history of seizures; Option C (Dimethyl fumarate) has a different mechanism that does not predispose to seizures.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuroimmunology",
    "explanation": "Dalfampridine is a potassium channel blocker used as a symptomatic therapy to improve walking in multiple sclerosis (MS). Its mechanism of increasing conduction in demyelinated axons, however, comes with the risk of lowering the seizure threshold. By blocking voltage\u2010gated potassium channels, dalfampridine prolongs the action potential in demyelinated nerve fibers. This action improves conduction but also increases neuronal excitability, which in susceptible individuals can precipitate seizure activity. The mechanism makes it particularly risky in patients with a history of seizures. Patients with MS often have multifocal neurologic involvement. In those with a history of seizures, administering dalfampridine may result in new-onset seizures or exacerbation of preexisting seizure disorders. A careful history is therefore essential before starting therapy. The evaluation includes a thorough clinical history focusing on seizure frequency, triggers, and previous EEG findings if available. Alternative causes of seizure activity should be ruled out. This information guides whether dalfampridine is a safe option or if other symptomatic treatments should be considered. First-line management of gait impairment in MS should include a complete neurologic and seizure history. If symptomatic therapy is indicated, dalfampridine is contraindicated in those with any seizure history. Alternative supportive therapies or physical rehabilitation should be considered. In pregnant or lactating patients, risks and benefits must be carefully evaluated; given the potential for seizure induction, use is generally avoided unless the benefits clearly outweigh the risk. Option A (Alemtuzumab) is an immunomodulatory agent with no direct effect on neuronal excitability; Option B (Dalfampridine) increases neuronal excitability and lowers the seizure threshold, making it contraindicated in patients with a history of seizures; Option C (Dimethyl fumarate) has a different mechanism that does not predispose to seizures. \u2022 Dalfampridine can lower the seizure threshold and is contraindicated in patients with any seizure history.  \u2022 Always review patient history and renal function before prescription, since the drug is renally excreted.  \u2022 Its role is strictly symptomatic and does not modify the underlying disease course in MS. Recent updates and FDA warnings have reinforced the seizure risk associated with dalfampridine. Current clinical guidelines emphasize stringent screening for any seizure history prior to its use, and ongoing studies continue to validate the importance of following contraindications in clinical practice.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following MRI characteristics is the best predictor of future disability in patients with multiple sclerosis?",
    "option_a": "baseline enhancing lesion number",
    "option_b": "baseline T2 lesion number",
    "option_c": "baseline T2 lesion volume",
    "option_d": "number of new enhancing lesions",
    "option_e": "number of new T2 lesions",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "MRI is a key tool in assessing the burden of disease in MS. Among various MRI parameters, the T2 lesion characteristics are extensively studied, and the lesion volume provides a quantitative measure of the overall disease burden. T2 hyperintense lesions in MS represent areas of demyelination, edema, and gliosis. Baseline T2 lesion volume reflects the cumulative extent of tissue injury, which can correlate with ongoing neurodegeneration and the degree of clinical impairment over time. A larger T2 lesion volume at baseline is associated with higher future disability because it indicates more widespread demyelination and potential axonal loss. Clinically, this means that patients with higher initial T2 lesion volumes are more likely to experience disability progression. In clinical practice, MRI is used to quantify both the number and volume of lesions. Differential imaging assessments include counting active (gadolinium-enhancing) lesions, new T2 lesions, and evaluating T1 hypointense lesions (black holes), each providing different insights into disease activity versus irreversible damage. In patients with high baseline T2 lesion volumes, early and possibly more aggressive disease-modifying treatment may be indicated to prevent future disability. For women who are pregnant or lactating, treatment choices must take into account drug safety profiles; many high-efficacy agents carry pregnancy risks, thus therapy may be adjusted or delayed with appropriate risk\u2013benefit analysis. Option A (baseline enhancing lesion number) indicates active inflammation but is less predictive of long-term disability. Option B (baseline T2 lesion number) does not capture the full extent of lesion burden compared to volume. Option C (baseline T2 lesion volume) best reflects total lesion burden and correlates with future disability. Options D and E (new enhancing lesions and new T2 lesions) show recent disease activity but are less indicative of cumulative damage. \u2022 T2 lesion volume is a robust predictor of long-term disability in MS.  \u2022 Lesion volume, rather than simple count, provides a more comprehensive picture of disease burden.  \u2022 Serial MRI evaluations are important to assess both inflammatory activity and the progression of tissue damage. Recent research and meta-analyses have continued to support baseline T2 lesion volume as a powerful predictor of future disability in MS. Advances in imaging techniques have further refined the quantification of lesion volume, and current clinical guidelines advocate its use in prognostication and monitoring of therapeutic response.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_33.png"
  },
  {
    "question": "Which MRI feature is most closely associated with progression of disability in multiple sclerosis patients?",
    "option_a": "Gadolinium-enhancing plaques",
    "option_b": "T1 hypointensities",
    "option_c": "T2 lesions",
    "option_d": "Cerebral atrophy",
    "option_e": "None of the above",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "MRI imaging in MS not only documents acute inflammatory lesions but also chronic neurodegenerative changes. Cerebral atrophy is the marker that best reflects the cumulative loss of brain tissue over time, which is closely linked to long-term disability. Chronic demyelination and ongoing neurodegeneration lead to the loss of both white and gray matter in the brain. Cerebral atrophy, which measures brain volume loss, represents the end result of these progressive pathological changes and correlates well with clinical disability. Patients with more pronounced cerebral atrophy frequently exhibit greater physical and cognitive deficits. The extent of atrophy has been shown to correlate with disability scores such as EDSS, making it a key prognostic marker. MRI is used not only to detect lesions but also to measure overall brain volume. Differential imaging markers include gadolinium-enhancing lesions (reflecting active inflammation), T1 hypointense lesions (indicative of permanent axonal loss), and T2 lesions (reflecting overall demyelination), yet cerebral atrophy provides the most direct correlation with clinical progression. Monitoring cerebral atrophy is important in long-term management. While current disease-modifying therapies primarily target inflammatory activity, there is increasing focus on neuroprotective strategies to reduce atrophy. In pregnant or lactating women, the choice of therapy must balance disease control with safety concerns, and non-teratogenic options are preferred. Serial brain volume measurements can help guide therapy adjustments over time. Option A (Gadolinium-enhancing plaques) indicates current inflammation rather than cumulative damage. Option B (T1 hypointensities) reflects areas of permanent damage but is less comprehensive than atrophy measurement. Option C (T2 lesions) indicates the presence of demyelination but does not quantify overall brain tissue loss. Option D (Cerebral atrophy) best captures the progressive neurodegenerative process associated with disability. \u2022 Cerebral atrophy is a strong marker for long-term disability in MS.  \u2022 It reflects the cumulative effects of both inflammatory and degenerative processes.  \u2022 Serial measurement of brain volume can be critical in evaluating treatment efficacy over time. Recent studies consistently emphasize the role of cerebral atrophy as the most reliable imaging biomarker for disability progression in MS. Emerging treatment strategies are increasingly targeting neuroprotection to mitigate atrophy, and current guidelines support the use of brain volume assessments in routine monitoring.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Alemtuzumab ADR: Hx of thyroiditis\nAlemtuzumab is a humanized monoclonal antibody therapy. It acts by targeting CD52, an antigen primarily expressed on T and B lymphocytes, resulting in their depletion and subsequent repopulation.\nSide effects include infusion-associated reactions, infection, malignancy (thyroid, melanoma and basal cell carcinoma). It is also well known to cause autoimmune adverse events including: ITP, thyroiditis, and nephropathy.",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuroimmunology",
    "explanation": "Alemtuzumab is a humanized monoclonal antibody used in the treatment of MS that targets CD52, leading to profound lymphocyte depletion and subsequent immune reconstitution. This mechanism predisposes patients to autoimmune complications. The immune reconstitution following alemtuzumab-induced lymphocyte depletion can be dysregulated. This dysregulation may result in the development of autoimmunity, with the thyroid gland being a common target. Autoimmune thyroiditis, along with other conditions like immune thrombocytopenia (ITP) and nephropathy, is an established adverse effect. Patients receiving alemtuzumab should be closely monitored for signs of thyroid dysfunction, such as symptoms of hyperthyroidism or hypothyroidism, which may develop months to years after therapy. Regular thyroid function tests are recommended post-treatment. Diagnosis involves monitoring thyroid-stimulating hormone (TSH) and free thyroid hormone levels, along with thyroid antibody assays when indicated. Differential diagnoses include primary thyroid disorders such as Graves' disease and Hashimoto's thyroiditis that can occur independently of treatment. Management includes routine thyroid function monitoring (typically every 3 months) for at least 48 months post-treatment. Initial management may involve endocrinology consultation for the titration of antithyroid medications or thyroid hormone replacement, depending on the clinical scenario. In pregnant patients, avoiding drugs with known thyroid toxicity is crucial; if thyroid dysfunction develops, careful management is required due to its potential impact on the fetus. During lactation, most thyroid medications are considered safe, but clinical monitoring is still essential. Even though explicit answer options are not provided, the key point is that thyroiditis is a well-documented autoimmune adverse event of alemtuzumab. Options that might focus solely on infusion reactions or malignancy profiles miss the critical autoimmune risk. A choice that denies the association between alemtuzumab and thyroiditis would be incorrect. \u2022 Autoimmune thyroiditis is one of the most common autoimmune complications following alemtuzumab therapy.  \u2022 Lifelong monitoring for thyroid dysfunction is critical, as abnormalities may present years after treatment initiation.  \u2022 Early detection and management of thyroid abnormalities can significantly mitigate long-term complications. Post-marketing studies and current guidelines continue to document thyroid autoimmunity as a significant adverse effect of alemtuzumab. Recent research focuses on identifying risk factors for developing autoimmune complications to improve patient selection and monitoring protocols.",
    "exam_year": "2019",
    "exam_type": "Part I"
  }
]